Black Diamond Therapeutics FY2025: net income $22.4M; cash $128.7M; silevertinib milestones Q2 2026

Black Diamond Therapeutics, Inc.

Net income of $22.4M for FY2025 vs net loss $69.7M in 2024; Q4 net loss $15.1M.
Cash, equivalents, investments $128.7M at Dec 31, 2025, funding operations into 2H 2028.
Silevertinib Phase 2 NSCLC update with preliminary DOR/PFS expected Q2 2026; randomized GBM trial to start Q2 2026.
R&D expenses $33.6M in FY2025, down 34% YoY due to restructuring and focus on silevertinib.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.